TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29358418

Group type: EXPERIMENTAL
Intervention: Decision-aid app
Number of subjects: 684

Group type: COMPARATOR
Intervention: Information-only app
Number of subjects: 684
Study: 27694489

Group type: EXPERIMENTAL
Intervention: Nutrition plus exercise group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Nutrition group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Exercise group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 92
Study: 22943662

Group type: EXPERIMENTAL
Intervention: 200 mg/day ketoprofen
Number of subjects: 409

Group type: COMPARATOR
Intervention: 300 mg/day ketoprofen
Number of subjects: 409
Study: 24301242

Group type: EXPERIMENTAL
Intervention: Desoximetasone spray 0.25% twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle spray twice daily
Number of subjects: 0
Study: 20598972

Group type: EXPERIMENTAL
Intervention: Telephonic health survey only (n = 865)
Number of subjects: 7687

Group type: EXPERIMENTAL
Intervention: Standard risk assessment (Framingham only) (n = 718)
Number of subjects: 7687

Group type: EXPERIMENTAL
Intervention: Comprehensive risk assessment in a dedicated mobile facility (n = 6,104)
Number of subjects: 7687

Group type: EXPERIMENTAL
Intervention: Advanced imaging with contrast-enhanced MRI and CT
Number of subjects: 7687
Study: 18223492

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation in PBC patients
Number of subjects: 118

Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 118
Study: 20102775

Group type: EXPERIMENTAL
Intervention: Diet I (low fat)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Diet II (low carbohydrate)
Number of subjects: 248
Study: 16282177

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control
Number of subjects: 258
Study: 12166347

Group type: EXPERIMENTAL
Intervention: Ibuprofen up to 1200 mg daily for 1-7 days
Number of subjects: 8633

Group type: COMPARATOR
Intervention: Paracetamol up to 3000 mg daily for 1-7 days
Number of subjects: 8633

Group type: COMPARATOR
Intervention: Aspirin up to 3000 mg daily for 1-7 days
Number of subjects: 8633

Group type: EXPERIMENTAL
Intervention: Patients with a history of non-ulcer GI disease (n = 371)
Number of subjects: 8633

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 8633
Study: 9829540

Group type: EXPERIMENTAL
Intervention: Ribozyme transduced cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control murine retroviral vectors
Number of subjects: 0
Study: 7988577

Group type: EXPERIMENTAL
Intervention: Epidural infusion of 0.083 mg ml-1 of diamorphine in 0.167% bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epidural infusion of 0.083 mg ml-1 of diamorphine in 0.9% NaCl solution (control)
Number of subjects: 40
Study: 2925353

Group type: EXPERIMENTAL
Intervention: Mazindol (2 mg, oral administration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11695211

Group type: EXPERIMENTAL
Intervention: New dentifrice formulation variant (Colgate Total Plus Whitening Toothpaste)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Colgate Total Toothpaste
Number of subjects: 97
Study: 29198062

Group type: EXPERIMENTAL
Intervention: Single bolus of tinzaparin at the start of haemodialysis
Number of subjects: 23

Group type: COMPARATOR
Intervention: Heparin in saline (H)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Heparin and albumin in saline (HA)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Heparin and albumin in combination with a citrate-containing dialysate (HAC)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Saline and using heparin-coated filters (Evodial®)
Number of subjects: 23
Study: 27210854

Group type: EXPERIMENTAL
Intervention: Manual percussion during postural drainage (PD) of the lower lobe
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Manual percussion during postural drainage (PD) of the upper lobe
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Manual percussion during postural drainage (PD) of the middle lobe
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Manual percussion during postural drainage (PD) of the upper and middle lobes
Number of subjects: 26
Study: 25080293

Group type: EXPERIMENTAL
Intervention: IGF1 titration
Number of subjects: 92

Group type: COMPARATOR
Intervention: High dose (67 μg/kg per day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Low dose (35 μg/kg per day)
Number of subjects: 92
Study: 22396129

Group type: EXPERIMENTAL
Intervention: HPV31 A variants
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: HPV31 B variants
Number of subjects: 470

Group type: COMPARATOR
Intervention: HPV31 C variants
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: HPV31 A variants (among women without CIN2/3 at first visit)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: HPV31 B variants (among women without CIN2/3 at first visit)
Number of subjects: 470
Study: 19141068

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 47
Study: 18525041

Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg daily for 3 months, then 300 mg daily for 3 months)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 599

Group type: COMPARATOR
Intervention: Aliskiren and Placebo
Number of subjects: 599
Study: 16005793

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer adhesive (Fuji Bond LC) combined with universal hybrid resin composite (Tetric Ceram)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer adhesive (Fuji Bond LC) combined with poly-acid modified resin composite (Hytac)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sclerotic lesions
Number of subjects: 73

Group type: COMPARATOR
Intervention: Non-sclerotic lesions
Number of subjects: 73
Study: 12025250

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (12.5 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.5% bupivacaine (12.5 mg)
Number of subjects: 90
Study: 10496549

Group type: EXPERIMENTAL
Intervention: Cognitive processing speed tests (Trailmaking B and Cancellation Random Figure tests)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cognitive speed factor
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Age and number of medications
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Modified Physical Performance Test (modified PPT)
Number of subjects: 125
Study: 7724354

Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study: 2140554

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (1.5 micrograms/Kg/min for 60 min)
Number of subjects: 20
Study: 7004257

Group type: EXPERIMENTAL
Intervention: Self-administered intravenous pethidine (0.25 mg/kg available at 10-min intervals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular pethidine (150 mg, repeated if necessary)
Number of subjects: 0
Study: 29463142

Group type: EXPERIMENTAL
Intervention: LAM + emergency contraception (EC) group
Number of subjects: 200

Group type: COMPARATOR
Intervention: LAM‐only group
Number of subjects: 200
Study: 29152934

Group type: EXPERIMENTAL
Intervention: AuraGain™
Number of subjects: 98

Group type: COMPARATOR
Intervention: LMA Protector™
Number of subjects: 98
Study: 26863353

Group type: EXPERIMENTAL
Intervention: Caplacizumab (10 mg daily)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 25002290

Group type: EXPERIMENTAL
Intervention: Levothyroxine (L‐T4) adjunctive treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 21422800

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE) during bed-rest
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inactive group (control)
Number of subjects: 20
Study: 20561741

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 85

Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 17323015

Group type: EXPERIMENTAL
Intervention: Brisk Walking (BW) at 6.2 ± 0.6 km/h for 30 minutes
Number of subjects: 14

Group type: COMPARATOR
Intervention: Moderate Walking (MW) at 4.5 ± 0.6 km/h for 30 minutes
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control for both interventions (cTnT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control for both interventions (LV function)
Number of subjects: 14
Study: 15750364

Group type: EXPERIMENTAL
Intervention: Biologically targeted imagery (BTI)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Critical thinking asthma management (CTAM)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 70
Study: 12172882

Group type: COMPARATOR
Intervention: Low-intensity training (LEX)
Number of subjects: 62

Group type: COMPARATOR
Intervention: High-intensity training (HEX)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Control (CON)
Number of subjects: 62
Study: 11465523

Group type: EXPERIMENTAL
Intervention: Doxepin (25-50 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 9604124

Group type: EXPERIMENTAL
Intervention: 250 mg artemisinin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 mg artemisinin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1000 mg artemisinin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Artemisinin (all doses)
Number of subjects: 8
Study: 8067230

Group type: EXPERIMENTAL
Intervention: Morphine/bupivacaine (MB) - morphine at 0.2 mg.h‐1 and bupivacaine at 10 mg.h‐1 for the first 24 h, then 5 mg.h‐1 for the second 24 h
Number of subjects: 85

Group type: COMPARATOR
Intervention: Fentanyl/bupivacaine (FB) - fentanyl at 20 micrograms.h‐1 and bupivacaine at 10 mg.h‐1 for the first 24 h, then 5 mg.h‐1 for the second 24 h
Number of subjects: 85
Study: 3267650

Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Küntscher-Y nail
Number of subjects: 0
Study: 48992

Group type: EXPERIMENTAL
Intervention: Colored visual illustrations
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Black and white visual illustrations
Number of subjects: 261

Group type: COMPARATOR
Intervention: Visuals (both black and white and color)
Number of subjects: 261
Study: 31707732

Group type: EXPERIMENTAL
Intervention: Hot water immersion (∼42°C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Thermoneutral control immersion (∼33°C)
Number of subjects: 10
Study: 30670669

Group type: EXPERIMENTAL
Intervention: Vibrating mesh nebulizer
Number of subjects: 12

Group type: COMPARATOR
Intervention: Jet nebulizer
Number of subjects: 12

Group type: COMPARATOR
Intervention: T-piece configuration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Large-spacer configuration
Number of subjects: 12
Study: 28454801

Group type: EXPERIMENTAL
Intervention: Anacetrapib 100mg daily
Number of subjects: 30449

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 30449
Study: 26424460

Group type: EXPERIMENTAL
Intervention: NtRTI group
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: raltegravir group
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 541
Study: 23727422

Group type: EXPERIMENTAL
Intervention: HBsAg-1018 (20 mcg rHBsAg + 3000 mcg 1018, a toll‐like receptor 9 agonist) given at 0, 4, and 24 weeks
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: HBsAg-1018
Number of subjects: 521

Group type: COMPARATOR
Intervention: HBsAg-Eng (4 double-doses of 2×20 mcg rHBsAg + 500 mcg alum given at 0, 4, 8, and 24 weeks)
Number of subjects: 521
Study: 21744284

Group type: EXPERIMENTAL
Intervention: Autograft with PRP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Autograft only
Number of subjects: 40
Study: 19129506

Group type: EXPERIMENTAL
Intervention: Antiplatelet medications at ICH onset
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 282
Study: 17029027

Group type: EXPERIMENTAL
Intervention: Individualized Academic Intervention (IAI)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Generic Academic Intervention (GAI)
Number of subjects: 167
Study: 15331886

Group type: EXPERIMENTAL
Intervention: SMOF 20%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lipovenoes 20%
Number of subjects: 12
Study: 11499858

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9088076

Group type: EXPERIMENTAL
Intervention: Intravenous Epoetin alfa (300 IU/kg twice weekly for 3 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Subcutaneous Epoetin alfa (100 IU/kg twice weekly for 3 weeks plus an i.v. bolus of 200 IU/kg at the first visit)
Number of subjects: 22
Study: 8095250

Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms MDI
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3742316

Group type: EXPERIMENTAL
Intervention: Group A - ten per cent methohexitone, 25 mg X kg‐1 (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group B - ten per cent methohexitone, 15 mg X kg‐1 (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group C - one per cent methohexitone, 15 mg X kg‐1 (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group A - ten per cent methohexitone, 25 mg X kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group C - one per cent methohexitone, 15 mg X kg‐1
Number of subjects: 60
Study: 30681494

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation with TEE
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cryoballoon ablation without TEE (non-TEE group)
Number of subjects: 80
Study: 29550045

Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily for 6 months) + Aspirin (81 mg for 6 months)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg once daily for 1 month) + Aspirin (81 mg for 6 months)
Number of subjects: 18
Study: 27489790

Group type: EXPERIMENTAL
Intervention: Application user group (n = 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Application nonuser group (n = 22)
Number of subjects: 44
Study: 25285423

Group type: EXPERIMENTAL
Intervention: SAF irrigation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: EndoActivator
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: EndoVac
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PUI
Number of subjects: 108

Group type: COMPARATOR
Intervention: Rotary instrumentation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Rotary instrumentation with various agitation regimens (syringe irrigation with needles, NaviTip FX, manual dynamic irrigation, CanalBrush)
Number of subjects: 108
Study: 22794270

Group type: EXPERIMENTAL
Intervention: Retrieval-mediated learning
Number of subjects: 0
Study: 19936713

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7.5% CO2 inhalation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control day (air inhalation)
Number of subjects: 12
Study: 17351275

Group type: EXPERIMENTAL
Intervention: 40% carbohydrate/45% fat diet (15% protein)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 60% carbohydrate/25% fat diet
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 52
Study: 15653003

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol 45 microg combined with levonorgestrel 30 microg
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol 45 microg combined with levonorgestrel 40 microg
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol and levonorgestrel (both doses)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 12966473

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10402244

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) as a single agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) in combination with dacarbazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) in combination with various cytotoxic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) combined with cisplatin at high doses
Number of subjects: 0
Study: 8756735

Group type: COMPARATOR
Intervention: Antithrombin III (AT III) and alpha 2-antiplasmin (alpha 2-AP) activity on day 0 and day 1 post-operation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Normalization of AT III and alpha 2-antiplasmin (alpha 2-AP) activity
Number of subjects: 40
Study: 1661657

Group type: EXPERIMENTAL
Intervention: L-arginine free base (5 mumol/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-arginine free base (5 mumol/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride (5 mumol/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-arginine hydrochloride (5 mumol/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-arginine free base (160 mumol/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-arginine free base (160 mumol/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride (160 mumol/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-arginine hydrochloride (160 mumol/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 6136292

Group type: EXPERIMENTAL
Intervention: Clobazam (10 mg twice a day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg twice a day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Clobazam and Lorazepam
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All groups (Clobazam, Lorazepam, Placebo)
Number of subjects: 70
Study: 3902533

Group type: EXPERIMENTAL
Intervention: Flunisolide inhalation, 500 mcg twice daily
Number of subjects: 99

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate inhaler, 100 mcg four times daily
Number of subjects: 99
Study: 29575090

Group type: EXPERIMENTAL
Intervention: SAPP (strength, agility, plyometric, and secondary prevention exercises)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SAPP + PERT (SAPP plus perturbation training)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both SAPP and SAPP + PERT
Number of subjects: 40
Study: 26987975

Group type: EXPERIMENTAL
Intervention: V158866 (5-300 mg single doses; 50-500 mg repeated doses)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: V158866 (300-500 mg/day)
Number of subjects: 51
Study: 23494104

Group type: COMPARATOR
Intervention: Ozone therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Control group (no LLLT or ozone therapy)
Number of subjects: 60
Study: 22527063

Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil
Number of subjects: 59

Group type: COMPARATOR
Intervention: Midazolam and fentanyl
Number of subjects: 59
Study: 19793142

Group type: EXPERIMENTAL
Intervention: Uninterrupted warfarin
Number of subjects: 101

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) - enoxaparin 1 mg/kg bd
Number of subjects: 101

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 101
Study: 18081914

Group type: EXPERIMENTAL
Intervention: MxA EIA assay
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: NAb-positive patients
Number of subjects: 51
Study: 16901550

Group type: EXPERIMENTAL
Intervention: 1-deamino 8-D-arginine vasopressin (DDAVP) spray
Number of subjects: 22
Study: 11427219

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9492666

Group type: EXPERIMENTAL
Intervention: Adjuvant psychological therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard medical care (Control)
Number of subjects: 73
Study: 8052077

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3399838

Group type: EXPERIMENTAL
Intervention: Latex condoms used during vaginal intercourse
Number of subjects: 40
Study: 31204262

Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Impaired Fasting Glucose (IFG)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Including physical activity in the model
Number of subjects: 342
Study: 28965138

Group type: EXPERIMENTAL
Intervention: REC + DVD
Number of subjects: 90
Study: 26599707

Group type: EXPERIMENTAL
Intervention: Antioxidants (N-acetylcysteine and ascorbate)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (200 μg/m(3) PM2.5)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 21
Study: 25433664

Group type: EXPERIMENTAL
Intervention: TDF/emtricitabine/efavirenz
Number of subjects: 1045

Group type: COMPARATOR
Intervention: ZDV/lamivudine/efavirenz
Number of subjects: 1045
Study: 22595974

Group type: EXPERIMENTAL
Intervention: Oral absorbable fat-soluble vitamin formulation (OAFSV)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional fat-soluble vitamin (FSV) supplementation
Number of subjects: 23
Study: 19940231

Group type: EXPERIMENTAL
Intervention: 10 mg Rd (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 45 mg Rd (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 75 mg Rd (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg Rd (multiple dose)
Number of subjects: 0
Study: 18567166

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metronidazole plus Amoxicillin
Number of subjects: 30
Study: 15764628

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery surgery
Number of subjects: 187

Group type: COMPARATOR
Intervention: On-pump coronary artery surgery
Number of subjects: 187